Complete dissection of right paratracheal lymph nodes (stations 2R and 4R) is critical to improve the prognosis of lung cancer patients: A retrospective cohort study
ConclusionsComplete RPND brings survival benefits to patients with right-sided NSCLC. We suggest complete RPND as a standard procedure for patients with right-sided NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - October 4, 2023 Category: Cancer & Oncology Authors: Kejia Zhao,
Jiandong Mei,
Binbin Hu,
Chenglin Guo,
Shiyou Wei,
Xudong Yang,
Zhenyu Yang,
Jian Zhang,
Yin Ku,
Yao Zheng,
Di Wu,
Shasha Li,
Yonghong Mao,
Yu Ding,
Lunxu Liu Tags: ORIGINAL ARTICLE Source Type: research
Pulmonary pleomorphic carcinoma treated with PD ‐1 inhibitor: Two case reports
Two patients diagnosed with PPC had a better prognosis after surgical resection combined with PD-1 inhibitor treatment. AbstractPulmonary polymorphic carcinoma (PPC) is a rare and poorly differentiated form of non-small cell lung cancer (NSCLC), accounting for just approximately 0.1% to 0.4% of all NSCLC cases. Historically, the conventional treatments for PPC have been linked to a grim prognosis. However, with the advent of immune checkpoint inhibitors (ICIs), including PD-1 inhibitors, for the management of NSCLC, our center has witnessed encouraging outcomes in two PPC patients who underwent PD-1 inhibitor therapy. The ...
Source: Thoracic Cancer - October 2, 2023 Category: Cancer & Oncology Authors: Tao Jiang,
Hao Wang,
Fei Xue,
Xuanpeng Wu,
Ming Ni,
Yuanyuan Wang,
Nanzheng Chen,
Yong Zhang,
Guangjian Zhang,
Junke Fu,
Xi Liu,
Qifei Wu Tags: CASE REPORT Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - October 1, 2023 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Clinical characteristics and prognostic impact of acute exacerbations in patients with interstitial lung disease and lung cancer: A single ‐center, retrospective cohort study
ConclusionAmong treatment options for patients with ILD-LC, CCRT was associated with an increased risk for AE. In addition, patients with AE had a higher mortality rate than patients without AE. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 30, 2023 Category: Cancer & Oncology Authors: Dong ‐gon Hyun,
Soo Jin Han,
Wonjun Ji,
Chang‐Min Choi,
Jae Cheol Lee,
Ho Cheol Kim Tags: ORIGINAL ARTICLE Source Type: research
Paclitaxel promotes mTOR signaling ‐mediated apoptosis in esophageal cancer cells by targeting MUC20
ConclusionThese data suggest that MUC20 is an important target of paclitaxel in esophageal cancer and promotes apoptosis through activation of mTOR signaling. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 29, 2023 Category: Cancer & Oncology Authors: Meng Li,
Zhen Feng,
Rui Han,
Benchuang Hu,
Renfeng Zhang,
Hui Wang Tags: ORIGINAL ARTICLE Source Type: research
Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC ‐MS/MS
ConclusionIt is imperative to acknowledge the potential drug –drug interactions mediated by CYP3A4 between azoles and lenvatinib, as these interactions hold significant implications for their clinical utilization. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 29, 2023 Category: Cancer & Oncology Authors: Mengming Xia,
Xueyi Song,
Zebei Lu,
Yu Wang,
Quan Zhou,
Peiwu Geng,
Shuanghu Wang,
Yunfang Zhou,
Qingjun Wu,
Aixia Han Tags: ORIGINAL ARTICLE Source Type: research
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
ConclusionThe results showed that the detection rate ofKRAS-positive lung cancers detected by blood and tissue samples differs, and that the detection rate of blood samples may be poor, especially in the case of mucinous adenocarcinoma with lung metastases only. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Yoshiaki Amino,
Siew ‐Kee Low,
Hironori Ninomiya,
Ayu Kiritani,
Keiki Miyadera,
Sho Kakuto,
Takahiro Akita,
Ryosuke Tsugitomi,
Ryo Ariyasu,
Ken Uchibori,
Satoru Kitazono,
Noriko Yanagitani,
Makoto Nishio Tags: ORIGINAL ARTICLE Source Type: research
Contrast ‐enhanced CT‐based radiomic analysis for determining the response to anti‐programmed death‐1 therapy in esophageal squamous cell carcinoma patients: A pilot study
ConclusionsThe combined model incorporating radiomic features and clinical CECT predictors helps to predict the response to anti-PD-1therapy in patients with ESCC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 25, 2023 Category: Cancer & Oncology Authors: Qinzhu Yang,
Haofan Huang,
Guizhi Zhang,
Nuoqing Weng,
Zhenkai Ou,
Meili Sun,
Huixing Luo,
Xuhui Zhou,
Yi Gao,
Xiaobin Wu Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - September 24, 2023 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Pyrotinib plus antiangiogenic agents for HER2 ‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
ConclusionIn this study, pyrotinib plus antiangiogenic agents demonstrated promising efficacy and were tolerable in HER2-altered NSCLC patients. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 23, 2023 Category: Cancer & Oncology Authors: Yaning Yang,
Guangjian Yang,
Weihua Li,
Xuezhi Hao,
Shuyang Zhang,
Xin Ai,
Siyu Lei,
Haiyan Xu,
Yan Wang Tags: ORIGINAL ARTICLE Source Type: research
Radiofrequency ablation for stage < IIB non ‐small cell lung cancer: Opportunities, challenges, and the road ahead
This article focuses on the application of RFA in early-stage non-small cell lung cancer patients, including the indication population, patient prognosis, and complications, and also summarizes the advantages and disadvantages of surgery versus RFA based on the current research base. At the same time, this article focuses on the development of RFA in combination with targeted or immunotherapy to provide new research directions for the application of RFA in lung cancer. AbstractPulmonary carcinoma represents the second common cancer for human race while its mortality rate ranked the first all over the world. Surgery remains...
Source: Thoracic Cancer - September 23, 2023 Category: Cancer & Oncology Authors: Qing Zhao,
Jing Wang,
Yi ‐li Fu,
Bin Hu Tags: REVIEW Source Type: research
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta ‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs
ConclusionThis NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Huang ‐Chih Chang,
Chin‐Chou Wang,
Chia‐Cheng Tseng,
Kuo‐Tung Huang,
Yu‐Mu Chen,
Yu‐Ping Chang,
Chien‐Hao Lai,
Wen‐Feng Fang,
Meng‐Chih Lin,
Hung‐Yi Chuang Tags: ORIGINAL ARTICLE Source Type: research
Elevated profiles of peripheral Th22, Th17, Th2 cells, and decreased percentage of Th1 cells in breast cancer patients
ConclusionTh22, Th17, Th1, and Th2 subsets may play an essential role in BC patients. Th22, Th17, Th1, and Th2 cells may have potential significance to be used as clinical markers in BC patients with different molecular classification. Th22 cells may have potential value in BC patients ’ outcomes prediction, providing clinical value. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Zhiguo Peng,
Xinyue Dong,
Miao He,
Yajing Zhao,
Yujia Liu,
Mo Li,
Guosheng Li,
Xiuwen Wang,
Li Li,
Yu Hu Tags: ORIGINAL ARTICLE Source Type: research
Intrinsic resistance to ROS1 inhibition in a patient with CD74 ‐ROS1 mediated by AXL overexpression
ConclusionsIn summary, we demonstrate that AXL overexpression is a mechanism of intrinsic resistance to ROS1 inhibitors. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Tara L. Peters,
Nan Chen,
Logan C. Tyler,
Anh T. Le,
Anastasios Dimou,
Robert C. Doebele Tags: ORIGINAL ARTICLE Source Type: research
Extracellular shuttling miR ‐21 contributes to esophageal cancers and human umbilical vein endothelial cell communication in the tumor microenvironment and promotes tumor angiogenesis by targeting phosphatase and tensinhomolog
ConclusionExo-miR-21-mediated communication between endothelial and cancer cells plays a pivotal role in promoting the angiogenesis of ESCC. Therefore, controlling exo-miR-21 could serve as a novel therapeutic strategy for ESCC by targeting angiogenesis. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Shanbo Zheng,
Juan Liao,
Mingjun Sun,
Ran Liu,
Junjie Lv Tags: ORIGINAL ARTICLE Source Type: research
